Urovalve comments on Millennium Research Group (MRG) report, US Markets for Urological Devices 2009

Company’s Surinate® Bladder Management System, designed to reduce catheter-associated urinary tract infections (UTIs), is positioned to benefit from favorable upgrade in Medicare reimbursement

NEWARK, N.J.--(EON: Enhanced Online News)--Urovalve agrees with analysis made in the recent industry report by Millennium Research Group (MRG)—US Markets for Urological Devices 2009—which concludes that due mainly to a favorable upgrade in Medicare reimbursement, the US intermittent catheter market will achieve a compound annual growth rate (CAGR) above 40% between 2008 and 2012.

“We believe we’re at the front of the wave”

An alternative to the frequent insertions and removals of urinary catheter devices—sometimes numerous times a day—Urovalve’s Surinate^® Bladder Management System is designed to provide for a single insertion in a 28-day cycle, leaving no tubes or other materials outside the body, such as a urine-collection bag, and enabling the individual to control the voiding of urine from his bladder by using a magnetized-valve control.

Besides being designed to greatly reduce the chance of urinary infection, the valved system will allow unobtrusive operation and lifestyle normalcy. The ability to avoid infection, especially of the hospital-related type, is a huge money-saving-incentive for the healthcare system.

“We believe we’re at the front of the wave,” said Harvey D. Homan, Ph.D., President and CEO of Urovalve. “The issue of the health problems associated with catheters is more serious than has been previously acknowledged, and we are therefore excited about the national attention this big problem is finally getting.”

Urovalve expects soon to begin a pilot study of its Surinate^® Bladder Management System—designed to improve the quality of life of men who suffer from acute or chronic urinary retention, an inability to empty the bladder caused by obstruction of the urethra.

Urovalve, Inc. (www.urovalve.com) is a privately held company located in the Enterprise Development Center at NJIT in Newark, New Jersey. The company develops superior medical devices to address problems associated with urinary flow and control.